Brief: HBM Holdings Says NMPA Approved Investigational New Drug Application For HBM7575 (SKB575) For Atopic Dermatitis
09/03/2026 10:37
March 9 (Reuters) - Hbm Holdings Ltd 2142.HK: NMPA APPROVES INVESTIGATIONAL NEW DRUGAPPLICATION FOR HBM7575 (SKB575) FOR ATOPIC DERMATITIS Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study